Dr. Mohamed is a board-certified, fellowship-trained nephrologist with the Kidney and Pancreas Transplant Program at Stanford Healthcare. She is a clinical associate professor in the Department of Medicine, Division of Nephrology.

Dr. Mohamed specializes in kidney and pancreas transplant outcomes and kidney transplant health equity. Conditions she treats include allografts rejection, recipient BK virus and CMV infection, and post-transplant lymphoproliferative disorder management. Dr. Mohamed is known for her personalized and comprehensive approach to patient care. She takes the time to understand her patients’ unique health needs and creates tailored care plans that fit their lifestyles.

Dr. Mohamed’s research interests include examining new approaches to improving kidney transplant long-term outcome including kidney transplant rejection and infection. She also seeks to develop better screening and monitoring guidance to help reduce post-transplant BK virus and CMV infection.

Dr. Mohamed’s published work can be found in peer-reviewed journals such as Clinical Transplantation, Transplant Infectious Disease and Transplantation. She has presented to her peers at international, national, and regional meetings, including at the American Transplant Congress and the American Society of Nephrology. She has also been invited to speak multiple times at King Faisal Hospital in Rwanda as well as in Kingdom of Saudi Arabia on topics like post-transplant lymphoproliferative disorder, update in kidney transplant rejection, and update in living-donor kidney transplantation.

Dr. Mohamed is a faculty fellow of Stanford Center for Innovation in Global Health, fellow of the American Society of Transplantation, a board of managers member of the AST Transplant Nephrology Fellowship Training Accreditation Program, member of the International Society of Nephrology and the American Society of Nephrology.

Clinical Focus

  • Nephrology
  • Kidney and Pancreas Transplant

Academic Appointments

Boards, Advisory Committees, Professional Organizations

  • Member, Board of Managers, American Society of Transplantation Transplant Nephrology Fellowship Training Accreditation Program (2023 - Present)
  • Global Health Faculty Fellow, Center for Innovation in Global Health (CIGH) (2023 - Present)

Professional Education

  • Fellowship: UCSF Dept of Nephrology (2010) CA
  • Board Certification: American Board of Internal Medicine, Nephrology (2009)
  • Fellowship: University of Maryland Medical Center (2009) MD
  • Fellowship: George Washington University Medical School (2004) DC
  • Internship: Bassett Medical Center NY
  • Residency: Bassett Hospital Internal Medicine Residency (2000) NY
  • Medical Education: University of Khartoum Faculty of Medicine (1992) Sudan

All Publications

  • Hypoalbuminemia is a risk factor for invasive fungal infections and poor outcomes in infected kidney transplant recipients CLINICAL TRANSPLANTATION Santos, A., Jorgenson, M. R., Osman, F., Srivastava, A., Misch, E., Garg, N., Aziz, F., Swanson, K. J., Mohamed, M., Djamali, A., Mandelbrot, D., Parajuli, S. 2023; 37 (10): e15052


    Invasive fungal infections (IFI), are estimated to occur in 2%-14% of kidney transplant recipients (KTRs) in the current era of immune suppression and are associated with high mortality rates. We hypothesized that hypoalbuminemia in KTRs is a risk factor for IFI and would be associated with poor outcomes.In this study, using data from a prospective cohort registry, we describe the frequency of IFI due to Blastomycosis, Coccidioidomycosis, Histoplasmosis, Aspergillosis, and Cryptococcus in KTRs with serum albumin levels measured 3-6 months before diagnosis. Controls were selected based on incidence density sampling. KTRs were divided into three groups based on the pre-IFI serum albumin level: normal (≥4 g/dL), mild (3-4 g/dL), or severe (<3 g/dL) hypoalbuminemia. Outcomes of interest were uncensored graft failure after IFI and overall mortality.A total of 113 KTRs with IFI were compared with 348 controls. The incidence rate of IFI among individuals with normal, mild, and severe hypoalbuminemia was 3.6, 8.7, and 29.3 per 100 person-years, respectively. After adjustment for multiple variables, the trend for risk of uncensored graft failure following IFI was greater in KTRS with mild (HR = 2.1; 95% CI, .75-6.1) and severe (HR = 4.47; 95% CI, 1.56-12.8) hypoalbuminemia (P-trend < .001) compared to those with normal serum albumin. Similarly, mortality was higher in severe hypoalbuminemia (HR = 1.9; 95% CI, .67-5.6) compared to normal serum albumin (P-trend < .001).Hypoalbuminemia precedes the diagnosis of IFI in KTRs, and is associated with poor outcomes following IFI. Hypoalbuminemia may be a useful predictor of IFI in KTRs and could be incorporated into screening algorithms.

    View details for DOI 10.1111/ctr.15052

    View details for Web of Science ID 001007475400001

    View details for PubMedID 37329297

  • Discordance in cytomegalovirus viremia in kidney recipients from the same donor is associated with the worst outcomes CLINICAL TRANSPLANTATION Zona, E., Jorgenson, M., Dolma, S., Santos, A., Garg, N., Aziz, F., Mohamed, M., Saddler, C. M., Smith, J. A., Mandelbrot, D., Parajuli, S. 2023; 37 (6): e14979


    Cytomegalovirus (CMV) is a common viral infection in kidney transplant recipients (KTR) that has been associated with negative outcomes. The effect on outcomes of concordance versus discordance in CMV between two different recipients of kidneys from the same donor is largely unknown.We reviewed all adult deceased donor kidney transplant recipients (DDKTs) for which both kidneys were transplanted to two different recipients at our center between 2014 and 2019. Recipient pairs from each donor were divided into groups based on concordance or discordance for the development of CMV viremia between the pair; concordant no CMV (cc-no-CMV) if neither KTR developed CMV, concordant CMV (cc-CMV) if both KTRs developed CMV. The discordant group was then further divided based on the individual development of CMV (dc-CMV) or lack of development of CMV (dc-no-CMV). Patient mortality and death-censored graft failure (DCGF) were outcomes of interest.Of 578 KTRs, 67% were cc-no-CMV, 5% were cc-CMV, 14% were dc-no-CMV, and 14% dc-CMV. Some of the baseline characteristics differ among the groups including a higher prevalence of high-risk serostatus (D+/R-) in cc-CMV (32%) and dc-CMV (32%). In multivariate analysis, with reference to cc-no-CMV, dc-CMV was associated with increased risk for DCGF (HR 3.13, 95% CI 1.58-6.19), and so was delayed graft function. Factors associated with increased risk of mortality were advanced recipient age and DGF. cc-CMV was neither associated with mortality nor DCGF.These findings support that in certain contexts, CMV viremia has adverse allograft outcomes, and this is highlighted when illustrated via discordance in CMV between pair kidneys from the same deceased donor.

    View details for DOI 10.1111/ctr.14979

    View details for Web of Science ID 000952680100001

    View details for PubMedID 36967240

  • Pre-transplant hypoalbuminemia is not associated with worse short-term outcomes among kidney transplant recipients CLINICAL TRANSPLANTATION Breyer, I., Astor, B. C., Srivastava, A., Aziz, F., Garg, N., Mohamed, M. A., Jorgenson, M. R., Mandelbrot, D. A., Parajuli, S. 2023; 37 (2): e14862


    Serum albumin is an indicator of overall health status, but it remains unclear how pre-transplant hypoalbuminemia is associated with early post-transplant outcomes.This study included all adult kidney transplant recipients (KTRs) at our center from 01/01/2001-12/31/2017 with serum albumin measured within 30 days before transplantation. KTRs were grouped based on pretransplant albumin level normal (≥4.0 g/dL), mild (≥3.5 - < 4.0g/dL), moderate (≥3.0 - < 3.5g/dL), or severe hypoalbuminemia (<3.0g/dL). Outcomes of interest included: length of hospital stay (LOS), readmission within 30 days, delayed graft function(DGF), and re-operation related to post-transplant surgical complications. We also analyzed rejection, graft failure, and death within 6 months post-transplant.A total of 2807 KTRs were included 43.6% had normal serum albumin, 35.3% mild, 16.6% moderate, and 4.5% severe hypoalbuminemia. Mild and moderate hypoalbuminemia were associated with a shorter LOS by 1.22 (p < 0.001) and 0.80 days (p = 0.01), respectively, compared to normal albumin. Moderate (HR: 0.58; 95% CI: 0.37-0.91; p = 0.02) and severe hypoalbuminemia (HR: 0.21; 95% CI: 0.07-0.68; p = 0.01) were associated with significantly lower rates of acute rejection within 6 months post-transplant.Patients with pre-transplant hypoalbuminemia have post-transplant outcomes similar to those with normal serum albumin, but with a lower risk of acute rejection based on the degree of hypoalbuminemia.

    View details for DOI 10.1111/ctr.14862

    View details for Web of Science ID 000925523200008

    View details for PubMedID 36380446